Critical Therapeutics kept at market outperform by Merrill

Merrill Lynch analyst Adam Cutler reiterated Critical Therapeutics Inc. at market outperform following news that the company's chief executive officer, president and director Paul Rubin is stepping down immediately. Key leadership positions of president and director are already filled, and the CEO position is being evaluated. Shares of the Lexington, Mass.-based biopharmaceutical company were down 43 cents, or 11.32%, at $3.37 on volume of 84,944 shares versus the three-month running average of 109,151 shares. (Nasdaq: CRTX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.